Circulating miRNA-155 as a Potential Biomarker for Coronary Slow Flow

Area of Science:

• Cardiovascular Biology
• Molecular Medicine
• Biomarker Discovery

Background:

• MicroRNA-155 (miRNA-155) is implicated in atherosclerosis and serves as an inflammation marker in cardiovascular diseases.
• Previous research indicates miRNA-155's involvement in inflammatory processes relevant to cardiovascular conditions.

Purpose of the Study:

• To investigate the association between plasma miRNA-155 levels and coronary slow flow (CSF).
• To determine if miRNA-155 can serve as a predictive biomarker for CSF.

Main Methods:

• Plasma miRNA-155 levels were quantified in 66 CSF patients and 66 controls using real-time quantitative polymerase chain reaction.
• Coronary flow velocity was assessed using the thrombolysis in myocardial infarction frame count (TFC) method.

Main Results:

• CSF patients exhibited significantly higher plasma miRNA-155 levels compared to controls (P < 0.05).
• miRNA-155 levels correlated positively with TFC and high-sensitivity C-reactive protein (hs-CRP).
• Plasma miRNA-155 and hs-CRP were identified as independent predictors for CSF (P = 0.032 and P = 0.013, respectively).

Conclusions:

• Elevated plasma miRNA-155 levels are observed in patients with CSF, suggesting a potential role in its pathogenesis.
• Increased plasma miRNA-155 may serve as a predictive biomarker for CSF.
• Further large-scale, multicenter studies are warranted to confirm miRNA-155's utility as a CSF biomarker.